Olav Bergheim is the Founder and Managing Director of Fjord Ventures LLC, a life sciences accelerator whose portfolio includes Adagio Medical, Anaxiom Corporation, Kato Pharmaceuticals, Prelude Corporation, Sonendo, and YAP Therapeutics — each founded by Olav. 

Previously he was General Partner at Domain Associates, where he established the Company Creation Initiative that led to the formation of VenPro, 3F Therapeutics (acquired by Medtronic), Vessix Vascular (acquired by Boston Scientific), Volcano Therapeutics (acquired by Philips), and Glaukos Corporation. 

Earlier, Olav spent 18 years in general management at Baxter Healthcare Corporation, serving as Corporate Group Vice President and President of Baxter’s Cardiovascular Group (now Edwards LifeSciences), as well as President of Immunotherapy Worldwide, President BioTech Europe, and President of Baxter Germany and General Manager of the Nordic area.